TY-9591
Phase 3Small molecule
TY-9591 is one of 126 small molecule programs targeting NSCLC. It is currently in Phase 3.
3
Indications
7
Total Trials
3
Active Trials
125
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Alecensa
RochePhase 3
Lazcluze
Johnson & JohnsonPhase 3
Lynparza
AstraZenecaPhase 3
TY-9591
TTYK Medicines, Inc
Phase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer2 trials
Tics1 trial
Growth1 trial
Lung Cancer1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TY-9591. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTYK Medicines, Inc